Descriptive epidemiology of sarcomas in Europe: Report from the RARECARE project

Abstract

We now differentiate between the requirements for new and revised submissions. You may choose to submit your manuscript as a single Word or PDF file to be used in the refereeing process. Only when your paper is at the revision stage, will you be requested to put your paper in to a 'correct format' for acceptance and provide the items required for the publication of your article. To find out more, please visit the Preparation section below. Highlights Highlights are mandatory for this journal for all article types except Letters to the Editor, Invited Previews or Editorial Comments. They consist of a short collection of bullet points that convey the core findings of the article and should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point). You can view example Highlights on our information site, but please note that despite the general information given there, for this journal, highlights are mandatory for all article types with the only excpetions being Letters to the Editor, Invited Previews or Editorial Comments.

Epidemiological study of soft‐tissue sarcomas in Ireland

“…Relative survival was very low in genitourinary tumors of females including uterus and highest in the STS of skin, similar to published reports 4, 15. The population based study from Europe reported lowest survival rates in STS of heart and mediastinum followed by uterine STS 4.…”

“…Common tumor sites in different age groups were also similar to other population‐based studies 2, 4.…”

“…The overall 5‐year relative survival rates over the period from 1994 to 2011 in Ireland were similar to those in the United Kingdom (56%, 1996–2010) and close to European averages (57.8%, 1995–2002) but lower than in United States (65.1%, 1975–2011) and certain areas in Europe where survival was up to 61% 4, 15, 16.…”

“…The RARECARE sarcoma study reports an overall higher incidence of STS in females as compared to males in Europe. This is attributed to the higher incidence of STS in uterus and breast in females as compared to the paratesticular organs in males in these countries 4. This was true in our report as ASR among females was highest in the uterus (1.44) and this was greater than ASR among males in any single site (highest in limbs: 1.09).…”

“…The population based study from Europe reported lowest survival rates in STS of heart and mediastinum followed by uterine STS 4. The incidence of STS in heart and mediastinum in Ireland was very low and hence it was not possible to calculate robust survival figures.…”